AK104 Monotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
AK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the
efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the
combination therapy. The aim of this study is to evaluate the efficacy and safety of AK104
monotherapy as neoadjuvant and adjuvant therapy for patients with resectable stage II-IIIA
NSCLC.